Peter Boross
Peter Boross
Associate Director at Genmab
Geverifieerd e-mailadres voor
Geciteerd door
Geciteerd door
Mechanisms of action of CD20 antibodies
P Boross, JHW Leusen
American journal of cancer research 2 (6), 676, 2012
The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor–mediated cross-linking
MB Overdijk, JHM Jansen, M Nederend, JJL van Bueren, RWJ Groen, ...
The Journal of Immunology 197 (3), 807-813, 2016
In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling
S de Haij, JHM Jansen, P Boross, FJ Beurskens, JE Bakema, DL Bos, ...
Cancer research 70 (8), 3209-3217, 2010
The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility
P Boross, VL Arandhara, J Martin-Ramirez, ML Santiago-Raber, ...
The Journal of Immunology 187 (3), 1304-1313, 2011
IgA EGFR antibodies mediate tumour killing in vivo
P Boross, S Lohse, M Nederend, JHM Jansen, G van Tetering, M Dechant, ...
EMBO molecular medicine 5 (8), 1213-1226, 2013
Coordinate expression of activating Fcγ receptors I and III and inhibiting Fcγ receptor type II in the determination of joint inflammation and cartilage destruction during …
K Nabbe, AB Blom, AEM Holthuysen, P Boross, J Roth, S Verbeek, ...
Arthritis & Rheumatism 48 (1), 255-265, 2003
The inhibitory receptor FcγRII reduces joint inflammation and destruction in experimental immune complex-mediated arthritides not only by inhibition of FcγRI/III but also by …
P van Lent, KC Nabbe, P Boross, AB Blom, J Roth, A Holthuysen, ...
The American journal of pathology 163 (5), 1839-1848, 2003
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
S Meyer, JHW Leusen, P Boross
MAbs 6 (5), 1133-1144, 2014
Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells
N van Montfoort, P AC’t Hoen, SM Mangsbo, MGM Camps, P Boross, ...
The Journal of Immunology 189 (1), 92-101, 2012
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden
P Boross, JHM Jansen, S de Haij, FJ Beurskens, CE van der Poel, ...
haematologica 96 (12), 1822, 2011
Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG
CE Van Der Poel, RA Karssemeijer, P Boross, JA Van Der Linden, ...
Blood, The Journal of the American Society of Hematology 116 (24), 5327-5333, 2010
Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking.
JHM Jansen, P Boross, MB Overdijk, JJL van Bueren, PWHI Parren, ...
Blood, The Journal of the American Society of Hematology 120 (21), 2974-2974, 2012
Staphylococcus aureus Formyl Peptide Receptor–like 1 Inhibitor (FLIPr) and Its Homologue FLIPr-like Are Potent FcγR Antagonists That Inhibit IgG-Mediated Effector Functions
AM Stemerding, J Köhl, MK Pandey, A Kuipers, JH Leusen, P Boross, ...
The Journal of Immunology 191 (1), 353-362, 2013
Effect of immune serum and role of individual Fcγ receptors on the intracellular distribution and survival of Salmonella enterica serovar Typhimurium in murine …
H Uppington, N Menager, P Boross, J Wood, M Sheppard, S Verbeek, ...
Immunology 119 (2), 147-158, 2006
Destructive arthritis in the absence of both FcγRI and FcγRIII
P Boross, PL van Lent, J Martin-Ramirez, J van der Kaa, MHCM Mulder, ...
The Journal of Immunology 180 (7), 5083-5091, 2008
Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice
P Boross, JHM Jansen, A Pastula, CE van der Poel, JHW Leusen
Immunology letters 143 (1), 44-52, 2012
The complex role of Fcγ receptors in the pathology of arthritis
P Boross, JS Verbeek
Springer seminars in immunopathology 28 (4), 339-350, 2006
Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting
S Meyer, M Nederend, JHM Jansen, KR Reiding, SR Jacobino, J Meeldijk, ...
MAbs 8 (1), 87-98, 2016
Characterization of a mutated IgA2 antibody of the m (1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages
S Lohse, C Brunke, S Derer, M Peipp, P Boross, C Kellner, T Beyer, ...
Journal of Biological Chemistry 287 (30), 25139-25150, 2012
A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA
GJA Rouwendal, MM van der Lee, S Meyer, KR Reiding, J Schouten, ...
MAbs 8 (1), 74-86, 2016
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20